Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related
deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal of malignancies, in
large measure, due to the propensity of PDAC cells to acquire resistance to …

Pancreatic ductal adenocarcinoma (PDAC), a prominent cause of cancer deaths worldwide,
is a highly aggressive cancer most frequently detected at an advanced stage that limits …

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all
cancer types. Its delayed diagnosis precludes curative resection, thus most of the current …

Pharmacological inhibition of KRAS> RAF> MEK1/2> ERK1/2 signaling has provided no
clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in
the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal …

Introduction: Pancreatic cancer has the worst survival rate of all cancers. The current
standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this …

Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide.
Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death worldwide, and the mortality of patients with PDAC has not significantly decreased …